Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis

BMC Musculoskeletal Disorders

Volumn 15, Issue 1, 2014, Pages

  Cawson, Matthew Richard ^a   Mitchell, Stephen Andrew ^b   Knight, Chris ^a   Wildey, Henry ^a   Spurden, Dean ^c   Bird, Alex ^c   Orme, Michelle Elaine ^d  

^a RTI HEALTH SOLUTIONS   (United States)

^b Decision Resources Group   (United Kingdom)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d Icera Consulting   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, PSORIATIC; BAYES THEOREM; BIOLOGICAL PRODUCTS; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; IMMUNOGLOBULIN G; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84892462205     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-15-26     Document Type: Review

References (55)

1. Psoriatic arthritis. Day MS, Nam D, Goodman S, Su EP, Figgie M, J Am Acad Orthop Surg 2012 20 1 28 37 10.5435/JAAOS-20-01-028 22207516
2. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rosen CF, Mussani F, Chandran V, Eder L, Thavaneswaran A, Gladman DD, Rheumatology (Oxford) 2012 51 3 571 6 10.1093/rheumatology/ker365 22157469
3. Psoriatic arthritis (PSA)-an analysis of 220 patients. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK, Q J Med 1987 62 238 127 41 3659255 (Pubitemid 17042878)
4. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM, Ballina Garcia J, Riestra Noriega JL, Lopez LC, Br J Rheumatol 1991 30 4 245 50 10.1093/rheumatology/30.4.245 1863819
5. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. Prey S, Paul C, Bronsard V, Puzenat E, Gourraud PA, Aractingi S, et al. J Eur Acad Dermatol Venereol 2010 24 Suppl 2 31 5 20443998
6. Diagnosis and Management of Psoriatic Arthritis A Practical Review. Young MS, Furfaro N, Rai A, Journal of the Dermatology Nurses' Association. 2009 1 5 283 293 2009 September/October 10.1097/JDN.0b013e3181ba2dba
7. Treatment recommendations for psoriatic arthritis. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, et al. Ann Rheum Dis 2009 68 9 1387 1394 2009 Sep 10.1136/ard.2008.094946 18952643
8. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, et al. Ann Rheum Dis 2012 71 1 4 12 10.1136/annrheumdis-2011-200350 21953336
9. Recent Developments in Management of Psoriatic Arthritis. Miedany YE, Curr Rheumatol Rev 2005 1 1 9 19 10.2174/1573397052954154
10. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Kristensen LE, Gulfe A, Saxne T, Geborek P, Ann Rheum Dis 2008 67 3 364 9 17644547 (Pubitemid 351281272)
11. Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis. Spadaro A, Ceccarelli F, Scrivo R, Valesini G, Ann Rheum Dis 2008 67 11 1650 1 10.1136/ard.2007.085951 18854519
12. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. Saad AA, Symmons DP, Noyce PR, Ashcroft DM, J Rheumatol 2008 35 5 883 90 18381787 (Pubitemid 351747132)
13. Indirect comparison of etanercept, infliximab, and adalumimab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator. Migliore A, Bizzi E, Broccoli S, Lagana B, Clin Rheumatol 2012 31 1 193 4 10.1007/s10067-011-1862-7 22005889
14. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Arthritis Rheum 2009 60 4 976 86 10.1002/art.24403 19333944
15. National Institute for Health and Clinical Excellence, Golimumab for the treatment of psoriatic arthritis London: NICE 2011 Available from: http://www.nice.org.uk/nicemedia/live/13441/54169/54169.pdf
16. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, et al. Health Technol Assess 2011 15 10 1 329 February 2011
17. Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis. Bojke L, Epstein D, Craig D, Rodgers M, Woolacott N, Yang H, et al. Rheumatology (Oxford) 2011 50 Suppl 4 v39 iv47 21859705
18. Systematic Review and network meta-analysis of biological therapy for the management of active psoriatic arthritis [SAT0298]. Spurden D, Orme ME, Mitchell S, Bird A, Ann Rheum Dis 2012 71 3 573
19. NICE. NICE Guidelines Manual, Appendix D http://www.nice.org.uk/media/ 633/21/The-guidelines-manual-2009-Appendix-D-Methodology-checklist-randomised- controlled-trials.pdf. 2009
20. National Institute for Health and Clinical Excellence (NICE), Updated guide to the methods and of technology appraisal London: NICE 2008
21. Dias S, Welton NJ, Sutton AJ, Ades AE, NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-analysis of Randomised Controlled Trials 2011
22. Bayesian methods in meta-analysis and evidence synthesis. Sutton AJ, Abrams KR, Stat Methods Med Res 2001 10 4 277 303 10.1191/096228001678227794 11491414 (Pubitemid 32691157)
23. Spiegelhalter DJ, Abrams KR, Myles JP, Bayesian Approaches to Clinical Trials and Health Care Evaluation Chichester, UK: Wiley 2004
24. Bayesian inference using Gibbs Sampling (BUGS), WinBUGS with DoodleBUGS version 1.4 Cambridge/London, UK http://www.mrc-bsu.cam.ac.uk/bugs/); 2003-7 [updated 2003-7; cited]; Available from: http://www.mrc-bsu.cam.ac.uk/bugs/
25. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. Caldwell DM, Ades AE, Higgins JP, BMJ 2005 331 7521 897 900 10.1136/bmj.331.7521.897 16223826 (Pubitemid 41502718)
26. Use of indirect and mixed treatment comparisons for technology assessment. Sutton A, Ades AE, Cooper N, Abrams K, Pharmacoeconomics 2008 26 9 753 67 10.2165/00019053-200826090-00006 18767896
27. Combination of direct and indirect evidence in mixed treatment comparisons. Lu G, Ades AE, Stat Med 2004 23 20 3105 24 10.1002/sim.1875 15449338 (Pubitemid 39334902)
28. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Bucher HC, Guyatt GH, Griffith LE, Walter SD, J Clin Epidemiol 1997 50 6 683 91 10.1016/S0895-4356(97)00049-8 9250266 (Pubitemid 27341818)
29. Indirect comparisons of competing interventions. Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, et al. Health Technol Assess 2005 9 26 1 134
30. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Ades AE, Sculpher M, Sutton A, Abrams K, Cooper N, Welton N, et al. Pharmacoeconomics 2006 24 1 1 19 10.2165/00019053-200624010-00001 (Pubitemid 43197227)
31. Office for National Statistics, United Kingdom Interim Life Tables 1980-82 to 2008-10 2011 http://www.ons.gov.uk/ons/rel/lifetables/interim-life- tables/2008-2010/rft-ilt-uk-2008-2010.xls (Accessed: 03 December 2012)
32. MIMS, Haymarket Business Media London, UK 2012
33. Curtis L, Unit costs of health and social care, Canterbury: Personal and Social Services Research Unit 2011 Available at: http://www.pssru.ac.uk/pdf/uc/ uc2011/uc2011.pdf. [Accessed 12 November 2012]
34. McHugh N, Chandler D, Griffiths C, Helliwell P, Lewis J, McInnes I, et al. BSR guideline for anti-TNFa therapy in psoriatic arthritis London: British Society for Rheumatology 2004
35. The Monthly Index of Medical Specialities (MIMS) http://www.mims.co.uk [Accessed: 12 November 2012]
36. Modelling the progression of rheumatoid arthritis:a two-country model to estimate costs to estimate costs and consequences of rheumatoid arthritis. Kobelt G, Jönsson L, Lindgren P, Young AKE, Arthritis Rheum 2002 46 2310 2319 10.1002/art.10471 12355478
37. Department of Health, Reference costs 2007-2008 London: NHS
38. Cost-effectiveness analysis of a psoriasis care instruction programme with dithranol compared with UVB phototherapy and inpatient dithranol treatment; Brit. Hartman M, Prins M, Swinkels OQ, et al. J Dermatol 2003 147 538 44 (Pubitemid 35015291)
39. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ, Lancet 2000 356 385 390 10.1016/S0140-6736(00)02530-7 10972371 (Pubitemid 30487495)
40. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Arthritis Rheum 2004 50 7 2264 2272 July 2004 10.1002/art.20335 15248226 (Pubitemid 38924405)
41. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD, et al. BMJ 2010 340 147 10.1136/bmj.c147 20124563
42. Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study. Atzeni F, Boccassini L, Antivalle M, Salaffi F, Sarzi-Puttini P, Ann Rheum Dis 2011 70 4 712 4 10.1136/ard.2010.130864 20810394
43. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Ann Rheum Dis 2005 64 8 1150 7 10.1136/ard.2004.032268 15677701 (Pubitemid 41113349)
44. Sustained Benefits of Infliximab Therapy for Dermatologic and Articular Manifestations of Psoriatic Arthritis. Results From the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Arthritis Rheum 2005 52 4 1227 1236 April 2005 10.1002/art.20967 15818699 (Pubitemid 40530131)
45. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Baranauskaite A, Raffayova H, Kungurov N, Kubanova A, Venalis A, Helmle L, et al. Ann Rheum Dis 2012 71 4 541 8 10.1136/ard.2011.152223 21994233
46. Japanese Infliximab Study i. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. Torii H, Nakagawa H, J Dermatol Sci 2010 59 1 40 9 10.1016/j.jdermsci.2010.04.014 20547039
47. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Arthritis Rheum 2005 52 10 3279 89 10.1002/art.21306 16200601 (Pubitemid 41447111)
48. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, et al. J Rheumatol 2007 34 5 1040 50 17444593 (Pubitemid 46774851)
49. A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. van Kuijk AWR, Gerlag DM, Vos K, Wolbink G, de Groot M, de Rie MA, et al. Ann Rheum Dis 2009 68 8 1303 9 10.1136/ard.2008.091389 18647851
50. Cost effectiveness of golimumab for the treatment of active psoriatic arthritis. Cummins E, Asseburg C, Prasad M, Buchanan J, Punekar YS, Eur J Health Econ 2012 13 6 801 9 10.1007/s10198-011-0335-x 21720868
51. Efficacy and safety of DMARDs in psoriatic arthritis: a systematic review. Pereda CA, Nishishinya MB, Martinez Lopez JA, Carmona L, Clin Exp Rheumatol 2012 30 2 282 9 22339882
52. Clinical outcomes in psoriatic arthritis: A systematic literature review. Palominos PE, Gaujoux-Viala C, Fautrel B, Dougados M, Gossec L, Arthritis Care Res (Hoboken). 2012 64 3 397 406 10.1002/acr.21552 22147535
53. Development of composite measures for psoriatic arthritis: a report from the GRAPPA 2010 annual meeting. Helliwell PS, Fitzgerald O, Mease PJ, J Rheumatol 2012 39 2 398 403 10.3899/jrheum.111233 22298265
54. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, et al. Ann Rheum Dis 2013 72 6 986 91 10.1136/annrheumdis-2012-201341 22798567
55. The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Olivieri I, de Portu S, Salvarani C, Cauli A, Lubrano E, Spadaro A, et al. Rheumatology 2008 47 11 1664 70 10.1093/rheumatology/ken320 18725374